TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06135311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse Width 260us
Description: electrodes placed per treatment arm, performed at bedtime, session time 30 min, frequency setting of 10Hz, pulse width setting 260us, intensity setting to patient's tolerance, duration 30 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse Width 50us
Description: electrodes placed per treatment arm, performed at bedtime, session time 30 min, frequency setting of 10Hz, pulse width setting 50us, intensity setting to patient's tolerance, duration 30 days
Study: NCT05764343

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immediate smoking cessation support
Description: Smoker patients with chronic airway diseases (asthma and/or COPD and/or bronchiectasis) will be evaluated for the inclusion criteria. Afterwards they will be randomized as routine support arm (as the current procedure of the care) and immediate support arm (intensive brief cessation advices following by the immediate arrangement of the appointment from the same clinic's smoking cessation service). Both arms will be followed remotely at first week and third months of the randomization regarding their quit status as well as their use of evidence based cessation treatments.
Study: NCT05537207

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low level laser therapy
Description: low level laser therapy (LLLT) on the acupuncture points. inadition to non-steroidal anti-inflammatory drugs.The parameters of the laser device are wave length of 904 nm, maximum average power of 5 milli Watts, a maximum repetition rate of 5 kHz, energy of up to 30 J/cm², and energy density of 2 J/cm2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-steroidal drugs
Description: All women will receive non-steroidal anti-inflammatory drugs in the form of Brufen (Ibuprofen), 400 mg, 3 times per day after meals, for 6 weeks, as described by their gynecologist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-steroidal drugs
Description: All women will receive non-steroidal anti-inflammatory drugs in the form of Brufen (Ibuprofen), 400 mg, 3 times per day after meals, for 6 weeks, as described by their gynecologist.
Study: NCT04391465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrophysiological Pacing
Description: Assess the MCA CBF velocity response at different paced heart rates.
Study: NCT06298565

Intervention type: BIOLOGICAL
Intervention: efgartigimod
Description: efgartigimod
Study: NCT04858802

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PROPEL Contour Sinus Implant
Description: 370 mcg mometasone furoate-coated sinus implant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon Sinus Dilation Alone
Description: No PROPEL Contour Sinus Implant
Study: NCT02793492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Misago® RX Self-expanding Peripheral Stent
Description: the Misago® RX Self-expanding Stent is a bare metal, nitinol stent
Study: NCT06297200

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Intensity Focused Ultrasound
Description: A noninvasive brain stimulation device using low-intensity focused ultrasound (LIFU) - ultrasound will be used to test whether noninvasive brain stimulation can effect pain, craving, and anxiety.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Intensity Focused Ultrasound - sham
Description: A sham condition that will mimic the application of LIFU without actually administering any ultrasound to the brain.
Study: NCT06510452

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2000 mg of Cefazolin
Description: receive 2000 mg of Cefazolin and 500 mg of Metronidazole IV dissolved in 100 ml NACL0.9%.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 500 mg of Metronidazole IV
Description: receive 2000 mg of Cefazolin and 500 mg of Metronidazole IV dissolved in 100 ml NACL0.9%.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NACL 0.9% 100 ml
Description: receive 100 ml NACL0.9% without any antibiotics in it.
Study: NCT06468033

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa-2b
Description: Pre-filled Syringe.~Dosage: up to 500mcg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a look-alike substance with the intervention (Ropeginterferon alfa-2b) that contains no active drug.
Study: NCT06186206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social media interventions for vaccine uptake
Description: Culturally Tailored Social Media Campaign: 4 communities receive a culturally tailored social media campaign via Facebook, focusing on geographical targeting. Content aligns with indigenous cultural norms and values, featuring educational materials, testimonials, and messaging addressing vaccine misconceptions on childhood routine and HPV vaccinations' importance and safety.~WhatsApp-Based Vaccine Training for CHW: 4 communities receive both the culturally tailored social media campaign and WhatsApp-based vaccine training for CHWs. Interactive training allows CHWs to engage in discussions, seek guidance, and enhance their ability to communicate effectively. This component targets vaccine hesitancy and boosts vaccine uptake rates.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social media interventions for vaccine uptake
Description: Culturally Tailored Social Media Campaign: 4 communities receive a culturally tailored social media campaign via Facebook, focusing on geographical targeting. Content aligns with indigenous cultural norms and values, featuring educational materials, testimonials, and messaging addressing vaccine misconceptions on childhood routine and HPV vaccinations' importance and safety.~WhatsApp-Based Vaccine Training for CHW: 4 communities receive both the culturally tailored social media campaign and WhatsApp-based vaccine training for CHWs. Interactive training allows CHWs to engage in discussions, seek guidance, and enhance their ability to communicate effectively. This component targets vaccine hesitancy and boosts vaccine uptake rates.
Study: NCT05750186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal Massage
Description: Abdominal massage is a noninvasive application that stimulates bowel movements by applying patting, kneading and vibration movements over the abdominal wall to the area where the intestines are located. It increases peristalsis, creates a mechanical and reflex effect on the intestines, reducing the individual's feeling of pain and discomfort.
Study: NCT06236139

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-STEAP1 CAR T-cells
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo NM bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study: NCT05362552

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urban Afforestation Program
Description: An afforestation program based on land cultivation and transplantation of several plants for 90 minutes will be implemented.
Study: NCT06395155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHP2306R1
Description: 100mg per capsule, BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHP2306R1
Description: 100mg per capsule, BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHP2306R1
Description: 100mg per capsule, BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHP2306R1
Description: 100mg per capsule, BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHP2306R1
Description: 100mg per capsule, BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHP2306R1
Description: 100mg per capsule, BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHP2306R2
Description: 75mg per Tab, BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHP2306R2
Description: 75mg per Tab, BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHP2306R2
Description: 75mg per Tab, BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHP2306R2
Description: 75mg per Tab, BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHP2306R2
Description: 75mg per Tab, BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHP2306R2
Description: 75mg per Tab, BID
Study: NCT05917704

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Guitar then physical therapy
Description: See arm/group descriptions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy then guitar
Description: See arm/group descriptions
Study: NCT06382207

Intervention type: DEVICE
Group type: OTHER
Intervention: Eko Duo electronic stethoscope
Description: A digital stethoscope with 1-lead electrocardiogram (ECG), the DUO, which pairs with a mobile application that allows the clinician to further engage with the device during and after a clinical visit. The application enables the clinician to visualize the sounds and electrical signals coming from the device in real time.

Intervention type: DEVICE
Group type: OTHER
Intervention: CORE 500 electronic stethoscope
Description: The CORE 500 has 3 electrodes that produce a 3 lead ECG, which can be viewed through the Eko app. The CORE 500 also has a user interface screen which provides a number of functions including confirming when all three electrodes have good skin contact, showing a single lead ECG wave, providing heart rate, allowing the user to switch between audio modes, allowing the user to take recordings, and providing AI analysis results for recordings.
Study: NCT05548439

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VBI-2901a
Description: Intramuscular injection of VBI-2901a, an investigational trivalent coronavirus vaccine that contains three coronavirus spike proteins with aluminum phosphate adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VBI-2901a
Description: Intramuscular injection of VBI-2901a, an investigational trivalent coronavirus vaccine that contains three coronavirus spike proteins with aluminum phosphate adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VBI-2901a
Description: Intramuscular injection of VBI-2901a, an investigational trivalent coronavirus vaccine that contains three coronavirus spike proteins with aluminum phosphate adjuvant.
Study: NCT04837053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital decision aid for physicians and patients
Description: The intervention consists of three parts: (1) the EKIT tool provides a systematic presentation of individual patient and disease-specific information; (2) it visualizes the fulfilment of the indication criteria recommanded in corresponding german guideline; (3) it presents health information about total knee replacement.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Care as usual within the included study sites.
Study: NCT05538195

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CEA-targeted CAR-T cells
Description: Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CEA-targeted CAR-T cells
Description: Administration method: intraperitoneal injection；Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
Study: NCT05640414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weekly Family Food Packages
Description: Families receive weekly family food packages for 6 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weekly Family Food Packages
Description: Families receive weekly family food packages for 6 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Health Group Sessions
Description: Families with children aged 6-17 years attend 6 monthly group sessions with cooking demonstrations
Study: NCT04880226

Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: Ongoing evaluations of magnetic resonance imaging (MRI) using the Philips Ingenua 1.5T scanner associated with MRI-guided procedures (e.g. ablations or biopsies) are essential to continued procedure improvement within the newly-built hybrid procedure suite.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Ongoing evaluations of magnetic resonance imaging (MRI) using the Philips Ingenua 1.5T scanner associated with MRI-guided procedures (e.g. ablations or biopsies) are essential to continued procedure improvement within the newly-built hybrid procedure suite.
Study: NCT06604143

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Goal Training
Description: Participants will engage in piano playing tasks using their affected hand and fingers. The training emphasizes learning to play and producing music. Feedback will be provided on various aspects of performance such as speed and accuracy, but specific details about finger movement or technique will not be given. The use of a wrist brace and monitoring of hand and arm positions will be consistent with standard practice.
Study: NCT06282224

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Performing endoscopic transnasal skull base surgery with AR-integrated endoscope
Description: To explore how to use augmented reality technology (AR) to highlight important anatomical structures in the neuroendoscopic field of view, optimize the endoscopic surgical field of view, make up for the shortage of simple endoscopic field of view, make it easier for surgeons to distinguish deep anatomical structures, and reduce the intraoperative and postoperative complications of transnasal endoscopic surgery.
Study: NCT06654141

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation
Description: Alveolar ridge preservation using xenograft (Bio-Oss Collagen®) and implant placement at 2 different time intervals (3 and 6 months)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar ridge preservation
Description: Alveolar ridge preservation using xenograft (Bio-Oss Collagen®) and implant placement at 2 different time intervals (3 and 6 months)
Study: NCT06662474

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1. cognitive stimulation
Description: sudoku, word games, and painting by numbers for 30 minutes per day, three days per week, for a duration of 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2. psychoeducation and cognitive stimulation
Description: sudoku, word games, and painting by numbers for 30 minutes per day, three days per week, for a duration of 12 weeks and also hold open group meetings for psychoeducation (1 meeting every 2 weeks, 6 meetings in total)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 3. no intervention
Description: maintaines their lifestyle up until their inclusion in the study without following additional measures
Study: NCT06088979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOUR006 - 20 MG
Description: TOUR006 20 MG

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOUR006 - 50 MG
Description: TOUR006 - 50 MG
Study: NCT06664385

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: concurrent physical exercise
Description: It consists of a periodization which consists of three moments adapted to the patient's needs distributed in 6 weeks and increasing the intensity gradually.
Study: NCT06666660

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin/Mineral supplements
Description: Each participant will be given 180 MVM tablets in bottles at baseline visit, and another 180 tablets at 6-month visit. Participants will be advised to take 1 tablet orally daily, in the morning before food. Participants will be asked to return the remainder of dispensed MVM tablets, along with the bottle when they come for visit 2 and visit 3. This is done for investigational product accounting and checking for adherence to the assigned treatment arm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant will be given 180 placebo tablets in bottles at baseline visit, and another 180 tablets at 6-month visit. Participants will be advised to take 1 tablet orally, daily, in the morning before food. Participants will be asked to return the remainder of dispensed placebo tablets, along with the bottle when they come for visit 2 and visit 3. This is done for investigational product accounting and checking for adherence to the assigned treatment arm. The placebo pills and bottles will be identical in appearance as MVM to ensure effective blinding.
Study: NCT06659705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI for PET / CT scan and 177Lu-EB-FAPI for therapy
Description: Gallium 68-labeled fibroblast activation protein inhibitor (FAPI) used as radiotracer during PET imaging.
Study: NCT06661798

Intervention type: PROCEDURE
Group type: OTHER
Intervention: orthognathic surgery
Description: Mandibular setback, Maxillary advancement, Bilateral sagital split osteotomy
Study: NCT04871100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol- Alcohol
Description: Transdiagnostic cognitive behavior therapy for emotional disorders modified to include CBT for alcohol use.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: referrals to VA care for SUD and anxiety
Study: NCT05868915

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HV-101
Description: Biological: HV-101~HV-101 is autologous tumor-infiltrating lymphocyte cells without genetic modification.~Drug: IL-2~Following cell infusion, the patient receives intravenous IL-2.~Drug: Fludarabine~Part of the non-myeloablative lymphocyte-depleting preparative regimen.~Drug: Cyclophosphamide~Part of the non-myeloablative lymphocyte-depleting preparative regimen.
Study: NCT06215664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Singularities Game
Description: Singularities is a theory-based, community-informed, web-accessible, roleplaying game-based intervention incorporating 4 primary components: fostering healthy identity development in a safe environment; encouraging help-seeking behaviors; encouraging use of productive coping; alcohol-harm reduction; and encouraging healthy internet and social media use.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food4Thought
Description: Food4Thought is an attention control condition in which we provide participants with similar amounts of research team contact and program contact as the intervention. Participants will play the game BAM! Dining Decisions developed by the Center for Disease Control and Prevention (CDC), which was designed to help teens make healthy food choices. Food4Thought will be delivered via Qualtrics.
Study: NCT05616273

Intervention type: OTHER
Intervention: Mixed Meal Tolerance Test (MMTT)
Description: At either Visit 1 or Visit 2, participants will be given Ensure HP or Fortisip (a drink containing the same amounts of carbohydrates, protein and fats as there would be in a meal; 6ml/kg to a max of 360mls), and have blood samples collected, to measure insulin (C-peptide), glucose, and glucagon, at specific intervals: -10, 0, 30, 60, 90, 120 minutes post meal. This test is used to measure how a participant's beta cells are working to produce insulin after a meal and to check for reactive hypoglycaemia.

Intervention type: OTHER
Intervention: Mixed Meal Tolerance Test (MMTT)
Description: At either Visit 1 or Visit 2, participants will be given Ensure HP or Fortisip (a drink containing the same amounts of carbohydrates, protein and fats as there would be in a meal; 6ml/kg to a max of 360mls), and have blood samples collected, to measure insulin (C-peptide), glucose, and glucagon, at specific intervals: -10, 0, 30, 60, 90, 120 minutes post meal. This test is used to measure how a participant's beta cells are working to produce insulin after a meal and to check for reactive hypoglycaemia.

Intervention type: OTHER
Intervention: Arginine Stimulation Test (AST)
Description: At either Visit 1 or Visit 2, and Visit 3, participants will be given a dose of Arginine Hydrochloride (5 g Arginine during 1 min) by intravenous injection, and have blood samples collected to measure insulin (C-peptide), glucose, and glucagon, at specific intervals: -10, 0, 2, 5, 10, 15 and 30 minutes following the Arginine bolus injection. This test is designed primarily to test the maximum insulin secretion capacity of a participant's beta cells.

Intervention type: OTHER
Intervention: Arginine Stimulation Test (AST)
Description: At either Visit 1 or Visit 2, and Visit 3, participants will be given a dose of Arginine Hydrochloride (5 g Arginine during 1 min) by intravenous injection, and have blood samples collected to measure insulin (C-peptide), glucose, and glucagon, at specific intervals: -10, 0, 2, 5, 10, 15 and 30 minutes following the Arginine bolus injection. This test is designed primarily to test the maximum insulin secretion capacity of a participant's beta cells.

Intervention type: OTHER
Intervention: Home Finger Prick Sample
Description: Participants will be provided with a kit to collect an optional home finger prick sample the day after each visit, and return the sample using the prepaid addressed padded envelope provided.

Intervention type: OTHER
Intervention: Home Finger Prick Sample
Description: Participants will be provided with a kit to collect an optional home finger prick sample the day after each visit, and return the sample using the prepaid addressed padded envelope provided.
Study: NCT05049798

Intervention type: DRUG
Intervention: Guselkumab
Description: Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with guselkumab, will be observed according to standard clinical practice.

Intervention type: DRUG
Intervention: IL-17i
Description: Participants will not receive any intervention as a part of this study. Participants who are initiating the treatment with IL-17i, will be observed according to standard clinical practice.